Drug Development Research

Aims & Scope

Drug Development Research publishes research papers and review-type articles covering all area within drug development: from target identification and validation and structure–activity relationship studies, through to post-market clinical reports.

Topics covered include but are not limited to medicinal and process chemistry, pharmacology, biotechnology and biopharmaceuticals, toxicology, drug delivery, formulation, pharmacokinetics, clinical trial reviews and post-approval/post-marketing evaluation.

The journal also welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy and strategy, and regulatory issues that involve drug discovery and development.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	4.2
2024	3.50

Journal Rank

Year	Value
2024	7313

Journal Citation Indicator

Year	Value
2024	9794

SJR (SCImago Journal Rank)

Year	Value
2024	0.756

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	70

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen

  Citation: 1302

  Authors: Michael R., Kenneth D.

• Magnetic nanoparticles for drug delivery

  Citation: 730

  Authors: Jon

• Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics

  Citation: 566

  Authors: David

• Comparison of the proteolytic susceptibilities of homologous L‐amino acid, D‐amino acid, and N‐substituted glycine peptide and peptoid oligomers

  Citation: 392

  Authors: Susan M., Reyna J., Simon, Ronald N., Janice M., Walter H.

• Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor‐targeted drug delivery vectors

  Citation: 389

  Authors: Giulio F., David G.I., Lawrence

• Dose translation between laboratory animals and human in preclinical and clinical phases of drug development

  Citation: 347

  Authors: Anroop, Mohamed Aly, Shery

• Ectonucleotidases: Some recent developments and a note on nomenclature

  Citation: 346

  Authors: Herbert

• Integrin α_vβ₃‐targeted cancer therapy

  Citation: 279

  Authors: Zhaofei, Fan, Xiaoyuan

• The Role of miR‐21 in Cancer

  Citation: 277

  Authors: Susan R., Chuan He, Lawrence M.

• Next‐generation antimalarial drugs: hybrid molecules as a new strategy in drug design

  Citation: 270

  Authors: Francis W., Akira

---